Known targets — ChEMBL curated mechanism
ADORA1ADORA2AADORA2BADORA3PDE3APDE3BPDE4APDE4BPDE4CPDE4D
The experimentally established mechanism targets of Phenylalanine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 6/20 | 0.73 |
| ▸ | ALPI | P09923 | 1/20 | 0.73 |
| ▸ | PKM | P14618 | 1/20 | 0.73 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.73 |
| ▸ | XIAP | P98170 | 1/20 | 0.73 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.54 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.54 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.54 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.54 |
| ▸ | LTA4H | P09960 | 2/20 | 0.51 |
| ▸ | NOS3 | P29474 | 1/20 | 0.50 |
| ▸ | NOS1 | P29475 | 1/20 | 0.50 |
| ▸ | NOS2 | P35228 | 1/20 | 0.50 |
| ▸ | ANPEP | P15144 | 1/20 | 0.49 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.49 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.49 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dl-Phenylalanine SCHEMBL28667668 | 1.00 | SLC7A5 (0.73) | SLC7A5ALPIPKMPTGS1XIAP | |
| Dl-Phenylalanine SCHEMBL4862934 | 0.93 | SLC7A5 (0.85) | SLC7A5ALPIPKMPTGS1XIAP | |
| Phenylalanine SCHEMBL3496164 | 0.93 | SLC7A5 (0.85) | SLC7A5ALPIPKMPTGS1XIAP | |
| Phenylalanine SCHEMBL1675272 | 0.93 | SLC7A5 (0.85) | SLC7A5ALPIPKMPTGS1XIAP | |
| Phenylalanine SCHEMBL6535507 | 0.93 | SLC7A5 (0.85) | SLC7A5ALPIPKMPTGS1XIAP | |
| Phenylalanine SCHEMBL218898 | 0.93 | SLC7A5 (0.85) | SLC7A5ALPIPKMPTGS1XIAP | |
| Phenylalanine SCHEMBL6033327 | 0.93 | SLC7A5 (0.85) | SLC7A5ALPIPKMPTGS1XIAP | |
| Phenylalanine SCHEMBL2063249 | 0.93 | SLC7A5 (0.85) | SLC7A5ALPIPKMPTGS1XIAP | |
| Dl-Phenylalanine SCHEMBL21816915 | 0.93 | SLC7A5 (0.85) | SLC7A5ALPIPKMPTGS1XIAP | |
| Phenylalanine SCHEMBL2679075 | 0.93 | SLC7A5 (0.85) | SLC7A5ALPIPKMPTGS1XIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1718667-B1 | HETEROCYCLIC SELF-IMMOLATIVE LINKERS AND CONJUGATES | GENENTECH INC (US) | 2013-01-09 | — | — | EP | claimed |
| US-7754681-B2 | Heterocyclic self-immolative linkers and conjugates | SEATTLE GENETICS, INC. (US) | 2010-07-13 | — | — | US | claimed |
| EP-1718667-A4 | HETEROCYCLIC SELF-IMMOLATIVE LINKERS AND CONJUGATES | GENENTECH INC (US) | 2009-04-08 | — | — | EP | claimed |
| US-20090041791-A1 | Heterocyclic self-immolative Linkers and Conjugates | SEAGEN INC. | 2009-02-12 | — | — | US | claimed |
| EP-1718667-A2 | HETEROCYCLIC SELF-IMMOLATIVE LINKERS AND CONJUGATES | GENENTECH, INC. (US) | 2006-11-08 | — | — | EP | claimed |
| US-20050256030-A1 | for linking drug moieties to ligands; comprises a peptide sequence that is a substrate for an intracellular enzyme, for example a cathepsin, that cleaves the peptide at an amide bond | SEAGEN INC. | 2005-11-17 | — | — | US | claimed |
| WO-2005082023-A2 | HETEROCYCLIC SELF-IMMOLATIVE LINKERS AND CONJUGATES | GENENTECH, INC. (US) | 2005-09-09 | — | — | WO | claimed |
| WO-2024034684-A1 | NEW DRUG COMPLEX | 興和株式会社 | 2024-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090041791-A1 | Heterocyclic self-immolative Linkers and Conjugates | CTSL, DNPEP, CTSE | SLC7A5 1184/4885ALPI 2071/4885PKM 2675/4885 |
| US-20050256030-A1 | for linking drug moieties to ligands; comprises a peptide sequence that is a substrate for an intracellular enzyme, for example a cathepsin, that cleaves the peptide at an amide bond | CTSS, CTSE, CTSL | SLC7A5 510/4885ALPI 2563/4885PKM 2723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.